These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38615067)

  • 21. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
    Hirama T; Shundo Y; Watanabe T; Ohsumi A; Watanabe T; Okada Y
    Clin Exp Med; 2024 Apr; 24(1):68. PubMed ID: 38578337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
    Martinez S; Sindu D; Nailor MD; Cherrier L; Tokman S; Walia R; Goodlet KJ
    Transpl Infect Dis; 2024 Jun; 26(3):e14279. PubMed ID: 38742601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Russo D; Schmitt M; Pilorge S; Stelljes M; Kawakita T; Teal VL; Haber B; Bopp C; Dadwal SS; Badshah C
    Lancet Haematol; 2024 Feb; 11(2):e127-e135. PubMed ID: 38142695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Royston L; Masouridi-Levrat S; Gotta V; Royston E; Pressacco-Brossier C; Abi Aad Y; Tonoli D; Karmime A; Jayo M; Van Delden C; Lescuyer P; Pfister M; Chalandon Y; Neofytos D
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0065722. PubMed ID: 35876579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review.
    Solano C; Giménez E; Albert E; Piñana JL; Navarro D
    J Med Virol; 2023 Aug; 95(8):e29005. PubMed ID: 37526411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
    Bansal R; Gordillo CA; Abramova R; Assal A; Mapara MY; Pereira MR; Reshef R
    Transpl Infect Dis; 2021 Apr; 23(2):e13487. PubMed ID: 33034124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
    Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
    Chen TT; David AP; Barthelmess EK; MacBrayne CE
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
    Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
    Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
    Veit T; Munker D; Kauke T; Zoller M; Michel S; Ceelen F; Schiopu S; Barton J; Arnold P; Milger K; Behr J; Kneidinger N
    Transplantation; 2020 Feb; 104(2):410-414. PubMed ID: 31385924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
    Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
    Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.